HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing
Executive Summary
A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version